540 likes | 682 Views
Extern. the. Conference. 6 September 2007. History. 6 year-old girl with fever for 3 days 4 days PTA, she had watery stool for 6-7 times a day, without blood or mucous. She had no rhinorhea or cough.
E N D
Extern the Conference 6 September 2007
History 6 year-old girl with fever for 3 days 4 days PTA, she had watery stool for 6-7 times a day, without blood or mucous. She had no rhinorhea or cough. 3 days PTA, she had high-graded fever. Her mother told that she was inactive and slept most of the time. She got over-the-counter drugs, paracetamol and ORS. Her diarrhea was improved but the other symptoms still persist.
History 6 year-old girl with fever for 3 days 2 days PTA, she had difficulty in voiding, increased in frequency, red-colored urine but no history of passing stone. She developed flank pain and still had high fever so her mother brought her to Siriraj hospital.
History 6 year-old girl with fever for 3 day She has no underlying disease and also no family history of renal disease, stones or urinary tract problems. No history of drug allergy
Physical Examination V/S T 38.6oC, P 120/min, RR 22/min, BP 104/60mmHg,Wt. 20 kg(P50), Ht. 122cm(P50-75) GA an alert Thai girl, good consciousness,looked weak, not pale, no jaundice,no edema HEENT dry lips, no sunken eyeballs, good skin turgor, pharynx & tonsils not injected,TM normal, no cervical lymphadenopathy RS normal breath sounds, no adventitious sound
Physical Examination CVS normal S1,S2, no murmur, all peripheral pulses 2+ Abdomen soft, not tender, no guarding/rigidity, rebound tenderness -ve, liver & spleen not palpable Back no scoliosis, bilateral CVA tenderness NS E4V5M6, otherwise within normal limits GU no labial adhesion
Problem List Could you help usfind out the problemin this patient??
Problem List • High-graded fever 3 days • Urinary symptoms 2 days • Dysuria • Urinary frequency • Red-colored urine • Bilateral CVA tenderness • Mild dehydration
Investigation Now it’s time for Extern, Please!!
Investigation CBC : Hb 12.3 g/dl, Hct 36.8%, WBC 16170(PMN 67.1%, L 26.3%), Platelet 259000
Investigation Bl.Chemistry : BUN 11, Cr 0.5,Na 137, K 3.8, Cl 103, HCO3 18
Investigation U/A : pH 8.0, Sp.Gr.1.015, protein 4+, sugar -ve, leukocyte +ve, nitrite +veRBC 20-30, WBC >200/HPFbacteria 2+, sq.epithelial cell 0-1
Investigation Gram stain : numerous PMNs,with small gram -ve rods (10-20/OF)
Investigation H/C, MUC : pending
Investigation • UrinalysisUrine Gram stain • Urine Culture • Complete blood count • Hemoculture • BUN, Cr, electrolytes
Investigation leukocytosis CBC : Hb 12.3 g/dl, Hct 36.8%, WBC 16170(PMN 67.1%, L 26.3%), Platelet 259000 Bl.Chemistry : BUN 11, Cr 0.5,Na 137, K 3.8, Cl 103, HCO3 18 U/A : pH 8.0, Sp.Gr.1.015, protein 4+, ketone 2+, sugar -ve, leukocyte +ve,nitrite +ve, RBC 20-30, WBC >200/HPFbacteria 2+, sq.epithelial cell 0-1 Gram stain : numerous PMNs,with small gram -ve rods (10-20/OF) H/C, MUC : pending Metabolicacidosis What does it mean??
Provisional Diagnosis • Acute pyelonephritiswith mild dehydration
Urinary UTI Tract Infection Extern ConferenceSeptember 2007
Background • Urinary tract is relatively common site of infection in infants and young children • Prevalence of UTI Girls Boys age <6yr 6.6% 1.8% school age 0.7-2.3% 0.04-0.2%
Background • UTIs are important because the cause acute morbidity and may result in long-term medical problems • Clinical presentation tends to be nonspecific and valid urine specimen can’t be obtained without invasive methods
Background • UTIs associate with renal scarring which may lead to HT and renal failure • Probably the most common preventable cause of end-stage renal diseases Relationship between renal scarringand number of UTIs
Pathophysiology • Ascending infection • Most common • Urinary stasis • Urinary tract abnormalities/Reflux • Infrequent/incomplete voiding • Hematogenous spreading • Non-specific symptoms • Common in neonates • Lymphatic spreading • Direct extension
Key aspect to the management of UTI 4 phases : • Recognizing the child at risk for UTI • Making the correct diagnosis • Short-term treatment of UTI • Evaluation of the child with UTI for possible urinary tract abnormality
Risk factors • Genetics • Female • Congenital anomalies • Behavioral • Constipation • Toilet training • Wiping from back to front • Tight clothing • Sexual activity
Risk factors • Biologic • Genitourinary abnormality • vesico-ureteral reflux • obstructive uropathy • neuropathic bladder • uncircumcised boy • labial adhesion • Voiding dysfunction • DM • Pregnancy • Immunocompromised host
Clinical Presentation • In younger children, UTI is difficult to make diagnosis and requires a high index of suspicion. Symptoms include vomiting, smelly urine, poor feeding, poor weight gain, altered temperature, abdominal distention, failure to thrive • For older children, more specific symptoms are usually elicited
Clinical Presentation Upper tract symptoms • High-graded fever • Flank pain • Nausea/vomitting • Severe malaise • Polyuria Lower tract symptoms • Low-graded fever • Dysuria • Frequency • Incontinence • Nocturnal enuresis
Key aspect to the management of UTI 4 phases : • Recognizing the child at risk for UTI • Making the correct diagnosis • Short-term treatment of UTI • Evaluation of the child with UTI for possible urinary tract abnormality
Diagnosis of UTI • Requires urine culture and should be obtained by urethral catheterization or suprapubic aspiration (SPA) • In older children, midstream clean-voided urine can be obtained for culture • Specimen should be process promptly, unless refrigerated to prevent bacterial overgrowth • The diagnosis cannot be established by a culture of urine collected in a bag
Diagnosis of UTI Based on the number of colony-forming units • SPA : any number • Urethral catheterization : >104 CFU/ml • Midstream clean-voided : • Boys >104 CFU/ml • Girls >105 CFU/ml
Urinalysis & UTI 2 most useful tests in urinalysis for possible UTI Leucocyte esterase: good sensitivity Nitrite: good specificity
Diagnosis of UTI Urinalysis cannot substitutea urine culture to document the presence of UTI,But valuable in selecting patients for prompt initiation of treatment while waiting for the results of urine culture
In this patient U/A : pH 8.0, Sp.Gr.1.015,protein 4+, sugar -ve, leukocyte +ve,nitrite +veRBC 20-30,WBC >200/HPFbacteria 2+, sq.epithelial cell 0-1
Key aspect to the management of UTI 4 phases : • Recognizing the child at risk for UTI • Making the correct diagnosis • Short-term treatment of UTI • Evaluation of the child with UTI for possible urinary tract abnormality
Treatment • If the child is seriously ill at presentation, the first steps in treatment are fluid resuscitation • Otherwise, the main aim is to initiate appropriate antibiotic therapy promptly Which antibiotic? Oral or intravenous? How long to treat?
Treatment • The majority of organisms causing UTI originate from the GI tract, most common being Escherichia coli • If the patient is assessed as toxic, dehydrated or unable to retain oral intake, initial ATB therapy should be administered parenterally and hospitalization should be considered • Otherwise, ATB should be initiated parenterally or orally
Treatment ATB for parenteral treatment of UTI In this case, we prescribedCeftriaxone 75 mg/kg/day, divided into 2 doses
Progress 15-17 Aug, 07
Progress Note 15/8/07 Specific treatment • Ceftriaxone 75mg/kg/day IV OD Symptomatic treatment • Correct dehydration with IV fluid • Paracetamol 10-15mg/kg/dose prn for fever • Observe clinical signs & symptoms
Treatment ATB for oral treatment of UTI
Treatment • If the patient have not had expected clinical response within 2 days, should be reevaluated and another urine specimen should be obtained • Routine reculturing after 2 days of ATB is not necessary if the clinical improves and the pathogen determined to be sensitive • Traditional length of treatment is 7- to 10-day ATB course, but prefer 14 days for ill-appearing children with clinical evidence of pyelonephritis
Key aspect to the management of UTI 4 phases : • Recognizing the child at risk for UTI • Making the correct diagnosis • Short-term treatment of UTI • Evaluation of the child with UTI for possible urinary tract abnormality
Further Management • After 7-14day course of ATB, children with UTI in the “high-risk group” should receive ATB in prophylactic dosage until the imaging studies are completed • Recurrent febrile UTIand renal scarring followsan exponential curve • Risk of recurrence is highest during the first months after UTI
Further Management High risk patient : • Age <5years • Pyelonephritis or septicemia • Recurrent UTIs • Voiding disorders/Incontinence • History, physical signs or family history of urinary tract anomalies, including VUR All should have a KUB ultrasound and VCUG
ATB prophylaxis Night-time dose of ATB to prevent further infection • Age <2mth : Amoxycillin 10mg/kg PO hs • Age >2mth : TMP/SMX 2mg of TMP/kg PO hs Some ATB for prophylaxis of UTI
U/S hydronephrosis normal VCUG VCUG No VUR No VUR VUR VUR Diuretic Renogram (UPJ obstruction) DMSAor IVP ATB prophylaxis Hygiene EducationStop Prophylaxis Further Investigation
VUR vesicoureteric reflux Grades of severity are categorized ; I to V based on the extent of the reflux and associated dilatation of ureter and pelvis
VUR vesicoureteric reflux • VUR is a self-limited disease, but the duration of the disease depends on severity • VUR gr.I, II : give ATB prophylaxis90% resolves in 5yr • VUR gr.III, IV (bilateral) age >6yr, gr.V (bilateral) age >1yrconsult urologist for reimplant surgery
Progress Note 16/8/07 • The patient becomes active, good appetite. She had no signs of dehydration, and her urinary symptoms was gone V/S : T 36.5oC, P 100/min, RR 20/min, BP 100/60mmHg U/A: pH 7, Sp.Gr.1.015, protein –ve, sugar –ve, leukocyte –ve, nitrite –ve, WBC 2-3/HPF, RBC 0-1/HPF, bacteria few, no epithelial cell
Progress Note 17/8/07 • MUC : E.coli (ESBL -ve) >105CFU/mlsensitive to 3rd generation cephalosporin • H/C : pending • After she was afebrile for 48hrs, the ATB was switched to oral form. We chose Ceftibuten (9mg/kg/day) PO once a day for complete 14day-course therapy • U/S KUB appointment on 9 September 07 • Discharge and follow-up 2wks later and plan for ATB prophylaxis